Telmisartan versus valsartan in patients with hypertension: Effects on cardiovascular, metabolic, and inflammatory parameters

Korean Circulation Journal

Volumn 41, Issue 10, 2011, Pages 583-589

  Lim, Sung Yoon ^a   Kim, Sun Won ^a   Kim, Eung Ju ^a   Kang, Jun Hyuk ^a   Kim, Su A ^a   Kim, Yun Kyung ^a   Na, Jin Oh ^a   Choi, Cheol Ung ^a   Lim, Hong Euy ^a   Han, Seong Woo ^a   Rha, Seung Woon ^a   Park, Chang Gyu ^a   Seo, Hong Seog ^a   Oh, Dong Joo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Hypertension; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; TELMISARTAN; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; B SCAN; BODY MASS; CARDIOVASCULAR RESPONSE; CAROTID ARTERY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INTIMA; LIPID BLOOD LEVEL; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONOTHERAPY; PATIENT COMPLIANCE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THICKNESS; TREATMENT OUTCOME; TUNICA MEDIA; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ULTRASOUND; WAIST CIRCUMFERENCE;

EID: 82055169454     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.10.583     Document Type: Article

References (27)

1. Sierra C, de la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens 2005;14:435-41. (Pubitemid 41152705)
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
3. Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009;39:180-4.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
5. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
6. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004;43:993-1002. (Pubitemid 38579904)
7. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7. (Pubitemid 38620211)
8. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001;103:448-54. (Pubitemid 32105987)
9. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-10. (Pubitemid 37059752)
10. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7. (Pubitemid 39319009)
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. (Pubitemid 15018832)
12. Hwang WM, Bae JH, Kim KY, Synn YC. Impacts of atherosclerotic coronary risk factors on atherosclerotic surrogates in patients with coronary artery disease. Korean Circ J 2005;35:131-9.
13. Safar ME, Smulyan H. Measurements of arterial stiffness: are they ready for clinical use? Current Cardiovascular Risk Reports 2008;2:268-73, doi: 10.1007/s12170-008-0050-z.
14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65. (Pubitemid 34084631)
15. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8. (Pubitemid 16119719)
16. Kim KI, Kim Y, Kim HJ, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from Korean Epidemiology Study on Hypertension (KEY study). Am J Hypertens 2008;21:884-9.
17. Neutel JM. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr Med Res Opin 2010;26:213-22.
18. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-7. (Pubitemid 37034566)
19. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10. (Pubitemid 39159163)
20. Song HG, Kim EJ, Seo HS, et al. Relative contributions of different cardiovascular risk factors to significant arterial stiffness. Int J Cardiol 2010;139:263-8.
21. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-9. (Pubitemid 43350177)
22. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-23.
23. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6. (Pubitemid 40684713)
24. Yamamoto K, Mano T, Yoshida J, et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005;23:393-400. (Pubitemid 40279643)
25. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96:4002-10.
26. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004;110:552-7. (Pubitemid 39031172)
27. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)